Allscripts announces second quarter 2016 results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Allscripts (MDRX) PT Raised to $15 at Piper Jaffray
August 5, 2016 8:10 AM EDTPiper Jaffray analyst Sean Wieland reiterated a Neutral rating but bumped his price target on Allscripts (NASDAQ: MDRX) to $15.00 (from $12.00) following record bookings driven by OptumCare win.
Wieland commented, "Allscripts beat bookings with the announcement of a win at OptumCare, a division of... More
Allscripts (MDRX) Reports In-Line Q2 EPS
August 4, 2016 4:04 PM EDTAllscripts (NASDAQ: MDRX) reported Q2 EPS of $0.14, in-line with the analyst estimate of $0.14. Revenue for the quarter came in at $386.5 million versus the consensus estimate of $403.13 million.
For earnings history and earnings-related data on Allscripts (MDRX) click here.
... More